World's First AI‐Designed Vaccine Tested in Humans For The First Time
In a pivotal moment for medicine, researchers at the University of Cambridge, in collaboration with spinout DIOSynVax, have successfully completed Phase 1 human clinical trials for the world's first vaccine whose active component was entirely designed by artificial intelligence. The experimental 'universal coronavirus vaccine', targeting the broader Sarbeco coronavirus family, proved safe and well-tolerated among 39 healthy volunteers, although early data indicated a modest immune response that did not significantly exceed pre-existing antibody levels.

















